ReviewGut microbes
Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.
Review in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis.PloS one · 2025Pooled it
- Current State of Knowledge Regarding WHO High Priority Pathogens-Resistance Mechanisms and Proposed Solutions through Candidates Such as Essential Oils: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Procyanidin-Rich Extract from Grape Seeds as a Putative Tool againstFoods (Basel, Switzerland) · 2020Article
- Trends inMicrobial genomics · 2020Review
- High Prevalence of Antibiotic Resistance in IranianJournal of clinical medicine · 2019Article
- Current understanding and management ofF1000Research · 2018Review
- The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City.Microbial drug resistance (Larchmont, N.Y.) · 2017Article
- First-line therapies forAnnals of gastroenterology · 2017Review
- Management of Helicobacter pylori infections.BMC gastroenterology · 2016Article
- Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions.World journal of gastroenterology · 2015Review
- Antibiotic treatment for Helicobacter pylori: Is the end coming?World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.World journal of gastroenterology · 2015Article
- Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.World journal of methodology · 2015Review
- Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.Clinics (Sao Paulo, Brazil) · 2015Article
- Fluoroquinolone-based protocols for eradication of Helicobacter pylori.World journal of gastroenterology · 2014Review
- A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.World journal of gastroenterology · 2014Review
- First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic.Ulusal cerrahi dergisi · 2014Article
- How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?World journal of gastroenterology · 2013Review
- Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.BMC gastroenterology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occurrence of resistance, especially to clarithromycin, renders the standard triple therapy used to cure Helicobacter pylori infection ineffective. This review presents the bacteriological and pharmacological basis for H. pylori therapy and the current recommendations. The third-line treatment must be based on clarithromycin susceptibility testing. If the bacteria are still susceptible, failure may come from problems of compliance, hyperacidity or high bacterial load which can be overcome. If the bacteria are resistant, different regimens must be considered, including bismuth and non-bismuth-based quadruple therapies (sequential or concomitant), as well as triple therapies where amoxicillin is administered several times a day to obtain an optimal concentration at the gastric mucosal level. The treatments are becoming more and more complex and ecologically unsatisfactory, waiting for new agents or vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.